Focusing on multiple myeloma (MM) and glioblastomas, they found that patients with tumours predicted to be GCN2-dependent (this prediction was done by looking at the transcriptional profile of patient samples available in the TCGA), had more aggressive cancers, which required earlier and sustained treatment both pharmacologically and using radiotherapy. Here, EIF2AK4 is linked to glioblastoma.